Synapse - Works

Results (13088)

Double-unit cord blood (CB) transplantation with haplo-identical CD34+ cells (haplo-dCBT) may speed neutrophil recovery although successful bridging is contingent on close haplo-winning CB unit HLA-match

Meeting Abstract

Politikos, I.; Devlin, S. M.; Mazis, C.; Maloy, M.; Naputo, K.; Afuye, A. O.; Bhatt, V.; Scaradavou, A.; O'Reilly, R. J.; Avecilla, S. T.; more...
Blood (2018)

Fulltext@MSK | Save

Metforminintreatment overcomes ATRA-resistance in acute promyelocytic leukemia FOXO3A expression

Meeting Abstract

Pereira-Martins, D. A.; Ortiz, C.; Franca-Neto, P. L.; Weinhauser, I.; Schiavinato, J. L.; Palma, P. V. B.; Bonaldo, C.; Koury, L. C. A.; Do Nascimento, M. C.; Melo, R. A. M.; more...
Blood (2018)

Fulltext@MSK | Save

Multicenter microbiota analysis indicates that pre-HCT microbiota injury is prevalent across geography and predicts poor overall survival

Meeting Abstract

Peled, J. U.; Gomes, A. L. C.; Stein-Thoeringer, C. K.; Slingerland, J. B.; Slingerland, A. E.; Weber, D.; Markey, K. A.; Smith, M.; Ponce, D.; Clurman, A.; more...
Blood (2018)

Fulltext@MSK | Save

A next-generation sequencing-based karyotyping algorithm reveals the genomic structure of acute myeloid leukemia

Meeting Abstract

Pavlick, D.; Montesion, M.; Heerema, N. A.; Severson, E. A.; Brennan, T.; Frampton, G. M.; He, J.; Byrd, J. C.; Levine, R. L.; Burd, A.; more...
Blood (2018)

Fulltext@MSK | Save

Acquired resistance to BRAF inhibition in HCL is rare and retreatment with vemurafenib at relapse can induce high response rates: Final results of a phase II trial of vemurafenib in relapsed HCL

Meeting Abstract

Park, J. H.; Lee, J. O.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Vemuri, S.; Abdel-Wahab, O. I.; Tallman, M. S.
Blood (2018)

Fulltext@MSK | Save

Maintenance with 5-azacytidine for acute myeloid leukemia and myelodysplastic syndrome patients

Meeting Abstract

Oran, B.; de Lima, M.; Garcia-Manero, G.; Thall, P. F.; Lin, R. T.; Alousi, A. M.; Hosing, C.; Kebriaei, P.; Popat, U.; Giralt, S.; more...
Blood (2018)

Fulltext@MSK | Save

Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: Preliminary results from the phase 2 CheckMate 436 trial

Meeting Abstract

Moskowitz, A. J.; Santoro, A.; Gritti, G.; Brice, P.; Cunningham, D.; Barr, P.; Kline, J.; Kuruvilla, J.; Johnson, N. A.; Mehta-Shah, N.; more...
Blood (2018)

Fulltext@MSK | Save

A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation

Meeting Abstract

Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
Blood (2018)

Fulltext@MSK | Save

High throughput droplet single-cell genotyping of transcriptomes (GoT) reveals the cell identity dependency of the transcriptional output of somatic mutations

Meeting Abstract

Nam, A. S.; Kim, K. T.; Chaligne, R.; Izzo, F.; Ang, C.; Omans, N.; Pastore, A.; Taylor, J.; Alonso, A.; Tam, W.; more...
Blood (2018)

Fulltext@MSK | Save

Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): First safety, efficacy and biomarker analyses from the phase II CAVALLI study

Meeting Abstract

Morschhauser, F.; Feugier, P.; Flinn, I. W.; Gasiorowski, R. E.; Greil, R.; Illes, A.; Johnson, N. A.; Larouche, J. F.; Lugtenburg, P. J.; Patti, C.; more...
Blood (2018)

Fulltext@MSK | Save